Minimizing metabolic activation during pharmaceutical lead optimization: progress, knowledge gaps and future directions.
Curr Opin Drug Discov Devel
; 11(1): 43-52, 2008 Jan.
Article
en En
| MEDLINE
| ID: mdl-18175266
ABSTRACT
Minimizing the potential for drug candidates to form chemically reactive metabolites that can covalently modify cellular macromolecules represents a rational strategy to reduce the risk of drug-induced idiosyncratic toxicity in humans. In this review, the approaches that are currently available for addressing this issue during the lead optimization phase of drug discovery, their limitations, and future scientific directions that have the potential to address these limitations are discussed.
Buscar en Google
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Farmacología
/
Preparaciones Farmacéuticas
/
Biotransformación
/
Diseño de Fármacos
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Curr Opin Drug Discov Devel
Asunto de la revista:
FARMACOLOGIA
/
TERAPIA POR MEDICAMENTOS
Año:
2008
Tipo del documento:
Article
País de afiliación:
Estados Unidos